Attached files
| file | filename |
|---|---|
| EX-99 - PRESS RELEASE - OWC Pharmaceutical Research Corp. | exh99_1.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C.
20549
___________________
FORM 8-K
___________________
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of report (date of earliest event reported): June 26, 2017
OWC
Pharmaceutical Research Corp.
(Exact Name of
Registrant as Specified in its Charter)
Commission File No.: 0-54856
| Delaware | 98-0573566 |
| (State of Incorporation) | (I.R.S. Employer Identification No.) |
| 30 Shacham Street. P.O.B. 8324 Petach Tikva, Israel | 4918103 |
| (Address of Principal Executive Offices) | (ZIP Code) |
Registrant's Telephone Number, including area code: 972 (0) 3-758-2657
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
¨ Written communications
pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨ Soliciting material
pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨ Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨ Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 8.01. Other Events. OWC Pharmaceutical Research Corp. (the "Registrant") is
reporting the issuance on June 27, 2017 of the attached press release,
announcing that its wholly-owned, Israel-based subsidiary, One World
Cannabis Ltd (OWC), has filed a patent application with the United States
Patent and Trademark Office for its active cannabinoid-based topical cream.
This new patent application follows the previously filed "provisional""
patent application. The added protection that this patent application should
provide for OWC's intellectual property will enable OWC to accelerate its
ongoing discussions and negotiations regarding scientific, medical and
commercial collaboration, based upon the fact that OWC's topical cream is
ready for marketing and commercial exploitation. Reference is made to the full text of the press release filed
as Exhibit 99.1 herewith. Item 9.01 Financial Statements and Exhibits. (a) The following documents are filed as exhibits to
this report on Form 8-K or incorporated by reference herein. Any document incorporated by
reference is identified by a parenthetical reference to the SEC filing that included such
document. Exhibit
No.
SIGNATURES Pursuant to the requirements of the Securities Exchange
Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
Description
99.1
Press Release dated June 27, 2017, filed herewith.
| OWC Pharmaceutical Research Corp. | ||
| By: /s/ Mordechai Bignitz | ||
| Name: Mordechai Bignitz | ||
| Title: Chief Executive Officer |
Date: June 27, 2017